CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2014--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
today announced that the Company will host its annual Research and
Development Day on Thursday, July 10, 2014 from 12:30 – 4:00pm ET at The
Hudson Theatre at the Millennium Broadway Hotel in New York City.
The Company will provide updates regarding its research and development
efforts and will host presentations by five key opinion leaders. The
Company will present clinical data, anticipated milestones and upcoming
plans for its programs targeting cancer stem cells. Lunch will be
served. Please RSVP to email@example.com.
Title: Verastem Research and Development Day 2014
Date: Thursday, July 10, 2014 at 12:30pm ET
Location: The Hudson Theatre at the Millennium Broadway
Hotel, 145 West 44th Street, New York, NY
Conference Call Dial-in (U.S.): 866-906-7447
Conference Call Dial-in (International): 617-939-0999
Conference Call Passcode: 5946305
Guest speakers scheduled to present include:
José Baselga, M.D., Ph.D.
Physician in Chief, Memorial Sloan-Kettering Cancer Center
Dr. Baselga’s research includes the development of novel molecular
targeted agents for cancer therapies, with special emphasis on breast
cancer. His research in preclinical and early clinical development of
therapies has helped develop a number of new targeted cancer-fighting
agents. Dr. Baselga was previously Chief of Medical Oncology at
Massachusetts General Hospital, Associate Chief of the MGH Cancer Center
and chairman of the Medical Oncology Service and director of the
Division of Medical Oncology, Hematology and Radiation Oncology at the
Vall d'Hebron Institute of Oncology in Barcelona, Spain. Dr. Baselga
completed a fellowship in medical oncology at Memorial Sloan-Kettering
Cancer Center where he remained as a faculty member of the Breast
Medicine Service until 1996. Dr. Baselga has published more than 250
peer-reviewed articles and over 400 abstracts and book chapters in his
career. He was previously the president of the European Society of
Medical Oncology, served on the board of directors of the American
Society of Clinical Oncology (ASCO) and is currently a member of the
board of directors of the American Association for Cancer Research
Raphael Bueno, M.D.
Associate Chief, Division of Thoracic Surgery, Brigham & Women’s
Dr. Bueno is a Professor of Surgery at Harvard Medical School, as well
as Associate Chief of Thoracic Surgery at Brigham and Women’s Hospital.
Dr. Bueno’s research focuses on molecular analysis of malignant pleural
mesothelioma and lung cancer, with a goal of improving diagnosis,
prognosis, and treatment of the diseases. Dr. Bueno has done extensive
research investigating peritoneal mesothelioma and pericardial
mesothelioma at the cellular level in an effort to identify more
effective treatment methods. Dr. Bueno completed his undergraduate and
medical degrees at Harvard University. Dr. Bueno completed a fellowship
in surgery at Brigham and Women’s Hospital, as well as a residency in
thoracic surgery at Massachusetts General Hospital. Dr. Bueno is board
certified in surgery, surgical critical care, thoracic surgery, and has
authored or co-authored more than 80 peer-reviewed journal articles. Dr.
Bueno is the Primary Investigator on the Window of Opportunity Study of
VS-6063 in participants with surgical resectable malignant pleural
Professor Dean Fennell, Ph.D., FRCP
Chair of Thoracic Oncology, University of Leicester, UK
Professor Fennell is a consultant physician and research scientist
specializing in the treatment of lung cancer, and particularly
mesothelioma for which he is internationally recognized. He is currently
leading UK and international clinical trials of novel targeted
therapies, and leads a translational research laboratory focused on
identifying genetic predictors of novel drug effectiveness, a recognized
priority area for improving outcomes in cancer research. Dr. Fennell has
published over 50 peer reviewed research articles, reviews and book
chapters on cancer pharmacology & clinical trials, is a regular reviewer
for several international scientific journals and funding agencies and
has been invited chair at national and international conferences.
Professor Fennell is the incoming president of the International
Mesothelioma Interest Group, member of the COMMAND International
Steering Committee and coordinating investigator for COMMAND in the UK.
Mary Hesdorffer, N.P.
Executive Director, Mesothelioma Applied Research Foundation
Ms. Hesdorffer is a nurse practitioner by training, who, for over 16
years has treated mesothelioma patients in a clinical setting. Ms.
Hesdorffer has published her own research in peer-reviewed journals and
is a medical professional well-known and highly regarded by mesothelioma
doctors and scientists. Ms. Hesdorffer has expertise in the development
and implementation of clinical trials and has lectured nationally on
topics pertaining to mesothelioma with particular emphasis on clinical
trials as well as symptom and disease management. Through her work at
the Mesothelioma Applied Research Foundation, Ms. Hesdorffer has been a
strong voice in urging increased transparency to the medical and legal
issues surrounding mesothelioma with a strong emphasis on ethics. Ms.
Hesdorffer received both her undergraduate and Masters of Science
degrees from the College of New Rochelle in New York.
Manish R. Patel, M.D.
Associate Director of Research, Florida Cancer Specialists & Research
Dr. Patel oversees the treatment of cancer patients in Phase 1 clinical
trials. In addition to his work at the Florida Cancer Specialists &
Research Institute, Dr. Patel also serves as the Associate Director of
Drug Development for the Sarah Cannon Research Institute, one of the
nation’s largest community-based clinical trial organizations. Dr. Patel
is Board Certified in Medical Oncology, Hematology, and Internal
Medicine. Dr. Patel completed his residency in Internal Medicine at
Vanderbilt University Medical Center and his fellowship in
Hematology/Oncology at the H. Lee Moffitt Cancer Center in Tampa. Dr.
Patel received his undergraduate degree from the University of Florida
and his M.D. from the University of Miami. Dr. Patel is an investigator
on the Phase 1/1b study of paclitaxel in combination with VS-6063 in
patients with advanced ovarian cancer (NCT01778803).
A replay of the webcast will be archived for 90 days following the
Replay webcast: http://bit.ly/1lJM20T
Replay Dial-in (U.S.): 888-799-6166
Replay Dial-in (International): 857-288-2550
Replay Passcode: 5946305
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to
treat cancer by the targeted killing of cancer stem cells. Cancer stem
cells are an underlying cause of tumor recurrence and metastasis.
Verastem is developing small molecule inhibitors of signaling pathways
that are critical to cancer stem cell survival and proliferation: FAK,
PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Source: Verastem, Inc.
Brian Sullivan, 617-252-9314